Consortium for Immunotherapeutics against Emerging Viral Threats

针对新兴病毒威胁的免疫治疗联盟

• 批准号: 10199909
• 负责人: Erica Ollmann Saphire
• 金额: $ 268.88万
• 依托单位: LA JOLLA INSTITUTE FOR IMMUNOLOGY
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-27 至 2022-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10199909
• 关键词: 2019-nCoV; Address; Affinity; Antibodies; Antibody Therapy; Antibody-mediated protection; Antigen-Antibody Complex; Area; Binding; Biological Assay; Blinded; Characteristics; Clinical; Clinical Research; Complement; Complex; Coronavirus; Cryoelectron Microscopy; Data; Data Set; Databases; Engineering; Ensure; Epitopes; FAIR principles; Funding; Geometry; Half-Life; Human; Immunoglobulin G; Immunotherapeutic agent; In Vitro; International; Knowledge; Maps; Mechanics; Mediating; Membrane; Myeloid Cells; Participant; Population; Predisposition; Proteins; Race; Research Project Grants; Risk; Sampling; Serologic tests; Side; Site; Speed; Structure; Surface; Surveys; System; Therapeutic; Therapeutic antibodies; Time; Transgenic Model; United States National Institutes of Health; Variant; Viral; clinical candidate; experimental study; mouse model; neonatal Fc receptor; next generation; novel; programs; therapeutic candidate; tool

ABSTRACT We recently galvanized the Coronavirus Immunotherapeutic Consortium, CoVIC, an international effort to conduct side-by-side analyses of leading therapeutic antibody candidates against the SARS-CoV-2 Spike protein contributed by a range of large and small companies and academic labs on multiple continents. CoVIC provides an opportunity for side-by-side analysis of the leading therapeutic candidates under the same assay conditions, as well as real-time collaborative assembly of a broader, deeper dataset on the activities and potencies of antibodies against SARS-CoV-2 than could be assembled by any single discovery effort alone. The currently funded CoVIC studies focus largely on characteristics of the Fab region of the IgG therapeutic: binding and mechanical neutralization, and analyze only spike from the original Wuhan reference strain of SARS-CoV- 2. The proposed supplement will provide support for critical components that are currently missing from CoVIC but which are needed to accelerate clinical advancement of antibodies that will be safe, efficacious and offer durable protection. We will determine Fc-mediated activities of the therapeutic antibodies, the likelihood or risk of enhancement from clinical candidates, and which epitopes and sites of and susceptibility to mutagenic escape. The resulting body of information will inform early and next-generation antibody therapies and will ensure that therapeutics are known which are responsive to emerging viral variants.

抽象的 我们最近镀锌了冠状病毒免疫治疗联盟，Covic，国际努力 对SARS-COV-2 SPIKE的领位治疗抗体进行并排分析 蛋白质由多大洲的一系列大型和小型公司和学术实验室贡献。 Covic 在同一测定法下为领先的治疗候选者提供并排分析的机会 条件以及有关活动和更深入的数据集的实时协作集会和 仅任何单一发现工作就可以弥补针对SARS-COV-2的抗体的效力。这 目前资助的COVIC研究主要关注IgG治疗的FAB区域的特征：结合 和机械中和，并仅分析sars-cov-原始武汉参考菌株的尖峰 - 2。拟议的补充剂将为Covic当前缺少的关键组件提供支持 但是，需要加快安全，有效和提供的抗体的临床发展 耐用的保护。我们将确定治疗性抗体的FC介导的活性，可能性或风险 临床候选者的增强，以及诱变逃逸的表现和位点以及易感性。 由此产生的信息将为早期和下一代抗体疗法提供信息，并确保 已知的治疗剂对新兴病毒变体有反应。